ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

Study demonstrates robust safety profile of Lupuzor™ with no ‘serious adverse events’ reported ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce analysis of the results from the open label six month extension study from its original Pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that it has entered into a subscription agreement with Lanstead Capital Investors LP (“Lanstead”), an institutional investor, together with a related sharing agreement (“Sharing Agreement”), raising approximately £2.66 million. Highlights Subscription for 26,565,200 new ordinary shares of 10 pence each in…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2018, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website www.immupharma.co.uk ImmuPharma’s…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2018 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £4.9 million (31 December 2017: £2.7 million) – Loss for…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on ongoing activities. Lupuzor™  Lupuzor™ is the Company’s late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial in 2018, ImmuPharma continues to look at opportunities which the Board believes over…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited (“Incanthera”) on its Nucant cancer programme. Background On 7 September 2018, ImmuPharma announced that it had signed Heads of Terms with Incanthera, a specialist oncology company, and that it had invested £2m into…

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce that on 25 February 2019, the peer reviewed research journal ‘Nature Communications’ published a fundamental scientific publication on the proprietary technology Urelix™ from UREkA Sarl (“Ureka”), ImmuPharma’s subsidiary. Ureka, based at the IECB in Bordeaux, France, is carrying out research…